Objection Handling: How Should Manufacturers Evolve to Meet the Clinical and Contracting Demands of Payers?
Navigating Market Access with Magnolia Summer 2024 Presentation.
Identifying the Market, Business and Reimbursement Potential for Cell Therapies
Magnolia was asked to assess which type of cell therapies and disease states offered the greatest potential for development, and also wanted to further understand the benefits of creating an autologous or allogeneic product.
Optimal Pricing Model Identification
A new, oral formulation of an existing infused product offered better adherence and less waste, but it was uncertain if these benefits would change payer, provider, and patient pain points or critical success factors for the product’s pricing strategy.
Developing a Comprehensive Launch Plan
Magnolia was engaged as a payer agency of record for a mental health digital therapeutic. Although the company had experience launching drugs in the U.S. market, the novelty of the digital therapeutic space was challenging, and the company did not have experience in mental health, nor a comprehensive launch plan in place across channels.
Magnolia’s Compendia Submission Helped Client Obtain Payer Coverage
Magnolia to evaluated the likelihood that a drug compendia would support an off-label dose for a drug with an FDA-approved maximum dose, and helped the client obtain stronger payer coverage with a compendia submission.
Telling a Value Story
A biopharma company engaged Magnolia to develop a value story for an orphan-designated treatment for an auto-immune disorder that was in Phase III development. The company’s product had a novel mechanism of action in comparison to the existing agents in development and would be the first new agent for the disease in years.
Payer Intelligence to Gather Feedback and Understand Potential Coverage and Reimbursement of an AI CVD Technology
A small technology company developed an AI-assisted platform that is used to improve accuracy of a CV diagnostic tool. The company asked Magnolia to gather payer feedback on clinical evidence for the platforms and provide insights on future coverage and reimbursement.
Payer Insights Survey: Gathering Early Perceptions of Health Plan Response to the Inflation Reduction Act of 2022
AMCP Spring 2024 Silver Poster.
Gauging how healthcare payers and pharmaceutical manufacturers are reacting to the Inflation Reduction Act of 2022
Magnolia engaged pharmacy directors, medical directors, and actuaries at health plans and PBMs to understand how payers are designing their plan offerings and adjusting their formularies in the coming years.
Gathering early perceptions of payer response to the Inflation Reduction Act of 2022
Magnolia Market Access surveyed medical and pharmacy directors at health plans and pharmacy benefit managers to understand how the IRA will affect the future of the pharmaceutical industry and access to care.